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1. Introduction
!
Colorectal cancer (CRC) represents a major cause
of morbidity and mortality in Western countries
[1]. Although CRC prevention, based on the iden-
tification and removal of precancerous adenoma-
tous polyps as well as on downstaging of CRC that
has already developed, has been shown to be
highly effective in high quality randomized and
observational studies [2–4], uptake in CRC
screening programs is still disappointingly low,
especially when compared with the high rate of
participation in breast, cervical, and prostate
screening programs [5,6]. Colon capsule endosco-
py (CCE; Given Imaging Ltd, Yoqneam, Israel) is a
new endoscopic technique which might have the
potential for improving uptake of CRC screening
[7–20]. It represents a minimally invasive and
painless imaging system that allows exploration
of the colon without the need for sedation and
gas insufflation. Recently, a second-generation
CCE device has been released that provides a
higher number of images per second and a larger
viewing angle [18–20].
Although CCE technology is now available on the
market in many countries, its clinical indications
as well as CCE reporting and post-CCE work-up
have not yet been standardized.
2.Methods
!
The European Society of Gastrointestinal Endos-
copy (ESGE) commissioned this Guideline, which
was then endorsed by its Governing Board. The
guideline development process was similar to
that used in creating other ESGE guidelines [21]:
it included meetings, telephone conferences, and
electronic media-based discussions among sub-
groups and members of the entire committee
during October 2010 and March 2011.
Subgroups were formed, each being charged with
a series of clearly defined key questions (see Ap-
pendix e1, available online). The committee chair
(J.P.G.) worked with subgroup leaders (S.A., O.E.,
G.G., M.P.) to identify pertinent search terms that
always included, as a minimum, “colon capsule
endoscopy” as well as words pertinent to specific
key questions. Searches were performed on Med-
line (via Pubmed), the Cochrane Library, Embase,
and the internet. Articles were first selected by ti-
tle; their relevance was then confirmed by review
of the corresponding manuscript, and publica-
tions with content that was considered irrelevant
were excluded. Additional articles, including ab-
stracts presented at international conferences,
were identified by manually searching the refer-
ence lists of retrieved papers. A central repository
of selected literature was made available to all
members of the guideline development group.
Evidence tables were generated for each key
question, summarizing the level of evidence of
the available studies. The number of articles selec-
ted for each task force is indicated in the Evidence
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PillCam colon capsule endoscopy (CCE) is an inno-
vative noninvasive, and painless ingestible cap-
sule technique that allows exploration of the co-
lon without the need for sedation and gas insuf-
flation. Although it is already available in Europe-
an and other countries, the clinical indications for
CCE as well as the reporting and work-up of de-
tected findings have not yet been standardized.
The aim of this evidence-based and consensus-
based guideline, commissioned by the European
Society of Gastrointestinal Endoscopy (ESGE) is
to furnish healthcare providers with a compre-
hensive framework for potential implementation
of this technique in a clinical setting.
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table (see●" Appendix e1 available online). For important out-
comes, articles were individually assessed by using the Method
for Evaluating Research and Guideline Evidence checklists as
amended by the Scottish Intercollegiate Guidelines Network
(SIGN) [22]. Evidence levels and recommendation grades used in
this guideline were those recommended by the amended SIGN
system (●" Table 1) [22]. Subgroups agreed by online communi-
cation on draft proposals that were presented to the entire group
for general discussion during a meeting held in February 2011
(Tarquinia, Italy). During the meeting and following discussion,
competing proposals for wording of recommendations or assign-
ing strength of evidence were resolved by formal voting. Consen-
sus was defined as agreement on a statement by ≥66% of partici-
pants; this was then termed a consensus statement, and num-
bered for convenience in the document. Where the guideline de-
velopment group was unable to achieve a ≥66% agreement on a
specific recommendation, the difference of opinion was formally
recorded and the reasons for dissent were noted. The results of
that discussion were incorporated into the subsequent guideline
version and again discussed using email.
Searches were re-run in March 2011.Studies that were published
after this date were not considered for inclusion. In March 2011,
the final draft was sent to all individual ESGE members. After in-
corporation of comments made by the individual ESGEmembers,
themanuscript was then sent to the Editorial Board of the journal
Endoscopy for critique and international peer review. It under-
went international peer review and the final version was ap-
proved by all members of the guideline development group.
Evidence statements and recommendations are stated in italics,
key evidence statements and recommendations are in bold. This
Guideline was issued in 2011 andwill be considered for review in
2014, or sooner if new evidence becomes available. Any updates
to the guideline in the interim period will be noted on the ESGE
website: http://www.esge.com/esge-guidelines.html.
3.Summary of statements and recommendations
!
Indications and contraindications for colon capsule
endoscopy (CCE)
CCE is feasible and safe and appears to be accurate when used in
average-risk individuals (Evidence level 2++ , Recommendation
grade C). There is a lack of specific studies based in the setting of
screening. CCE screening may be cost-effective if it increases screen-
ing uptake compared with colonoscopy (Evidence level 4, Recom-
mendation grade D).
Patients at high risk for CRC, because of alarm symptoms or signs,
or a family or personal history of CRC, are at increased risk of ad-
vanced colorectal neoplasia and cancer. These patients should be
referred to colonoscopy. However, in patients for whom colonosco-
py is inappropriate or not possible, the use of CCE could be discus-
sed with the patient (Evidence level 4, Recommendation grade D).
CCE is a feasible and safe tool for visualization of the colonic muco-
sa in patients with incomplete colonoscopy and without stenosis
(Evidence level 3, Recommendation grade D). Randomized studies
comparing CCE with radiological imaging or conventional endo-
scopic modalities are needed to confirm the efficacy of CCE in this
setting and to better define the patients for whom CCE is most suit-
able (Evidence level 4, Recommendation grade D).
To date, there are insufficient data to support the use of CCE in the
diagnostic work-up or in the surveillance of patients with suspect-
ed or known inflammatory bowel disease (IBD) (Evidence level 4,
Recommendation grade D). On the basis of preliminary data, CCE
may be useful to monitor inflammation in ulcerative colitis, which
may help to guide therapy (Evidence level 4, Recommendation
grade D).
Contraindications for CCE are similar to those for small-bowel cap-
sule endoscopy. The use of sodium phosphate as a booster should
be avoided in patients at increased risk of sodium phosphate toxicity.
Other kinds of booster preparations are under investigation andmay
be considered in patients at increased risk of sodium phosphate toxi-
city (Evidence level 4, Recommendation grade D).
The risk of capsule retention with CCE is very low. In the case of
capsule retention either in the small or the large bowel, endoscopy
or surgery can be considered on the basis of the clinical background
(EL, 3 Recommendation grade D).
Bowel preparation for CCE
Patients must follow a liquid diet the day before the procedure,
whilst the role of low-residue diet is yet to be clarified (Evidence
level 4, Recommendation grade D).
A total of 4L of polyethylene glycol should be administered before
the CCE procedure. A split-dosage regimen with intake the day before
and on the day of the examination seems advisable to increase the
tolerability and the efficacy of the preparation (Evidence level 4, Re-
commendation grade D).
Table 1 Definitions of categories for evidence levels and recommendation
grades used in this Guideline [21].
Levels of evidence
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs
with a very low risk of bias
1 + Well conducted meta-analyses, systematic reviews, or RCTs with
a low risk of bias
1– Meta-analyses, systematic reviews, or RCTs with a high risk of bias
2 ++ High quality systematic reviews of case– control or cohort
studies
High quality case– control or cohort studies with a very low risk of
confounding or bias and a high probability that the relationship is
causal
2 + Well conducted case – control or cohort studies with a low risk
of confounding or bias and a moderate probability that the
relationship is causal
2– Case– control or cohort studies with a high risk of confounding or
bias and a significant risk that the relationship is not causal
3 Nonanalytic studies, e. g. case reports, case series
4 Expert opinion
Grades of recommendation
A At least one meta-analysis, systematic review, or RCT rated as
1 ++ , and directly applicable to the target population; or
A body of evidence consisting principally of studies rated as 1+ ,
directly applicable to the target population, and demonstrating
overall consistency of results
B A body of evidence including studies rated as 2 + + , directly
applicable to the target population, and demonstrating overall
consistency of results; or
Extrapolated evidence from studies rated as 1 + +or 1 +
C A body of evidence including studies rated as 1 – or 2+ , directly
applicable to the target population and demonstrating overall
consistency of results; or
Extrapolated evidence from studies rated as 2 + +
D Evidence level 2– or 3 or 4; or
Extrapolated evidence from studies rated as 2 +
RCT, randomized controlled trial.
Note: The grade of recommendation relates to the strength of the evidence on which
the recommendation is based. It does not reflect the clinical importance of the
recommendation.
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Booster preparations need to be given to improve capsule egestion
rates and to complete visualization of the colonic mucosa (Evidence
level 4, Recommendation grade D). In patients without contraindica-
tions to sodium phosphate, boosters based on sodium phosphate
should be used (Evidence level 1+ , Recommendation grade B). Low-
dose sodium phosphate boosts have been shown to achieve an ade-
quate CCE egestion rate and should be preferred over higher sodium
phosphate doses (Evidence level 4, Recommendation grade D).
During the CCE procedure, the use of prokinetics is recommended
when the capsule stays in the stomach longer than 1 hour (Evidence
level 4, Recommendation grade D).
Written and oral information about CCE bowel preparation should
be delivered by healthcare professionals (physician or nurse) in-
volved in gastroenterology and with experience regarding the tech-
nique (Evidence level 4, Recommendation grade D).
Reporting and work-up of CCE results
The CCE report should provide information on the quality of pre-
paration, technical details of the examination, completeness of the
procedure, and on the significant findings (polyps/masses ≥6mm or
≥3polyps, irrespective of size) in a standardized fashion (Evidence
level 4, Recommendation grade D). In particular, size, morphology,
and location should be separately described for each polyp.Extraco-
lonic findings should also be reported when clinically meaningful
(Evidence level 4, Recommendation grade D).
Patients found to have a polyp ≥6mmat CCE, aswell as thosewith ≥3
polyps irrespective of size, should be sent for post-CCE colonoscopy for
polypectomy (Evidence level 4, Recommendation grade D).
Patients without significant findings at CCE should repeat CCE or a
different screening test after 5 years, unless bowel preparation at
CCE was inadequate (Evidence level 4, Recommendation grade D).
If overall bowel preparation was inadequate or CCE was incom-
plete, repetition of CCE or another colon imaging study should be
considered (Evidence level 4, Recommendation grade D).
4. Indications and contraindications for colon capsule
endoscopy (CCE)
!
CCE is feasible and safe and appears to be accurate when used in
average-risk individuals (Evidence level 2++ , Recommendation
grade C). There is a lack of specific studies based in the setting of
screening. CCE screening may be cost-effective if it increases screen-
ing uptake compared with colonoscopy (Evidence level 4, Recom-
mendation grade D).
In the validation of noninvasive colorectal imaging tests for CRC
screening and diagnosis, detection of advanced neoplasia has
been regarded as a reliable intermediate end point. For instance,
computed tomography (CT) colonography and immunochemical
fecal tests have been extensively validated using this end point
[23,24]. The validation process generally consists in assessing
the accuracy of noninvasive tests for advanced neoplasia, using
colonoscopy as an independent “gold standard” [25]. Because
noninvasive colorectal imaging tests cannot provide a histologi-
cal diagnosis, morphological criteria (i. e. polyp/mass ≥6mm in
size, or ≥3 polyps) are accepted as surrogate markers of advanced
neoplasia (high grade dysplasia, presence of villous component,
or malignancy) [7,8,23]. Matching algorithms, based on size
matching between the noninvasive test and the reference stand-
ard, have usually been incorporated in these studies to assure a
reliable assessment of the new tests [7,8,23].
Of note, the accuracy values shown in these studies are indepen-
dent from the prevalence of the disease. This means that values
assessed in a population enriched with regard to advanced neo-
plasia remain accurate in settings where different prevalences
may be expected, such as in asymptomatic average-risk popula-
tions.
The average sensitivity of the first generation of CCE (CCE-1) de-
vices for significant findings (≥6mm size, or ≥3 polyps irrespec-
tive of size) was 58% [7–17], substantially improving to 86%with
the second generation CCE (CCE-2) devices (●" Table2) [18–20].
These rates are higher than the 50% cutoff for sensitivity that
has been adopted by the American Cancer Society to define a
test acceptable for screening purposes [25], and are comparable
or superior to those of other noninvasive screening tests [26]. It
should be emphasized that the ultimate aim of CRC screening is
not to detect all the prevalent CRC (i.e. 100% sensitivity), but to
Table 2 Diagnostic accuracy of colon capsule endoscopy (CCE) for significant findings (polyps 6mm in size, or 3 polyps).
Author, year Patients with significant
findings, n (%)
Sensitivity Specificity PPV NPV
Eliakim, 2006 [7]1 16 (19) 50% 82% 40% 88%
Schoofs, 2006 [8]1 13 (36) 77% 70% 59% 84%
Van Gossum, 2009 [9]1 87 (27) 64% 84% 60% 86%
Gay, 2010 [11]1 67 (53) 76% 76% 78% 74%
Sacher-Huvelin, 2010 [12]1 112 (21) 39% 88% 47% 85%
Pilz, 2010 [13]1 6 (10) 50% 75% 19% 93%
Spada, 2011 [14]1 13 (33) 62% 85% 67% 82%
Spada, 2011 [15]1 7 (15) 100% 95% 78% 100%
Eliakim, 2009 [18]2 18 (19) 89% 76% 46% 97%
Spada, 2011 [20]2 45 (41) 84% 64% 62% 85%
All studies 384 (20) 63% 83% 57% 86%
CCE-1 studies 321 (19) 58% 85% 57% 86%
CCE-2 studies 63 (30) 86% 71% 56% 92%
PPV, positive predictive value; NPV; negative predictive value.
1 First-generation colon capsule endoscopy (CCE-1) studies.
2 Second-generation (CCE-2) studies.
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reduce the prevalence significantly, also taking into account
other variables, such as uptake, safety, costs, and complications.
The apparently low specificity shown by CCE (see●" Table2; in-
cluding CCE-2) has been shown to be mainly related to size mis-
matching between CCE and colonoscopy, resulting in an overesti-
mation of size by CCE for diminutive lesions [18–20]. Although
diminutive polyps do not represent a primary target for noninva-
sive imaging tests (see the work-up section below), it cannot be
excluded at this stage that their detection may nevertheless be
associated with CRC prevention, so that this low specificity
should not be considered to be a significant obstacle to CCE im-
plementation in a screening setting [20].
CCE has consistently been shown to be a very safe procedure: no
major complication has been reported in over 1500 procedures,
of which around 40% were in asymptomatic individuals [7–20].
CCE also appears to be a feasible procedure, with a very low rate
of technical failures (i. e. 3%) and a high capsule excretion rate of
about 90% [7–20].
On the other hand, no data are available on the possible uptake of
CCE in a screening context. A previous cost–effectiveness analy-
sis has compared first-generation CCE with colonoscopy in a
screening setting [27]. Although CCE was not a cost-effective al-
ternative when equal uptake was assumed, it became an efficient
option when it was assumed that uptake of CCE would be higher
than that of colonoscopy for CRC screening, a premise that has
not been demonstrated yet.
Patients with non-alarm symptoms do not appear to be at in-
creased risk of colorectal neoplasia [28]. For this reason, noninva-
sive tests may be proposed in this setting as an alternative to co-
lonoscopy [29]. Among noninvasive tests, however, imaging tests
might be preferred over non-imaging ones (i. e. fecal tests), be-
cause of the ability, that may be regarded as clinically useful, to
detect non-neoplastic conditions (e.g. vascular malformations).
Among noninvasive imaging tests, CCE may be applicable in the
context of screening because of the abovementioned considera-
tions of feasibility, safety and accuracy. Although CCE has been
shown to detect diverticular disease as well as inflammatory
changes of the bowel mucosa [7–20], no study has specifically
addressed its performance in detecting non-neoplastic altera-
tions.
Patients at high risk for CRC, because of alarm symptoms or signs,
or a family or personal history of CRC, are at increased risk of ad-
vanced colorectal neoplasia and cancer. These patients should be
referred for colonoscopy. However, in patients for whom colonosco-
py is inappropriate or not possible, the use of CCE could be discus-
sed with the patient (Evidence level 4, Recommendation grade D).
Patients with alarm symptoms (rectal bleeding, anemia, weight
loss, intestinal subocclusion) are at increased risk of colorectal
neoplasia. In particular, these patients are at a 5–10-fold in-
creased risk of malignancy [30]. Patients with a positive fecal
blood test are also at increased risk for CRC and advanced neopla-
sia [24–26]. In this setting, a test with a very high sensitivity is
desirable and, therefore, colonoscopy or, alternatively, computed
tomography (CT)-colonography or barium enema should be con-
sidered as the primary options [31]. CCE sensitivity for cancer is
still unclear. As shown in●" Table3, the sensitivity of first-gen-
eration CCE (CCE-1) for CRC detection was suboptimal compared
with that of colonoscopy [7–17]. Although CCE-2 would seem to
be more sensitive (i. e. 4 cancers detected out of 4 true-positive
cases, thus sensitivity 100%) [18,20] than CCE-1 for malignancy
detection, data from a larger number of patients are needed be-
fore recommending the use of CCE-2 in this setting. Moreover,
subocclusive symptoms represent a contraindication to CCE be-
cause of the high risk of capsule retention.
CCE is a feasible and safe tool for visualization of the colonic muco-
sa in patients with incomplete colonoscopy and without stenosis
(Evidence level 3, Recommendation grade D). Randomized studies
comparing CCE with radiological imaging or conventional endo-
scopic modalities are needed to confirm the efficacy of CCE in this
setting and to better define the patients for whom CCE is most suit-
able (Evidence level 4, Recommendation grade D).
The cecal intubation rate in colonoscopy has been reported to
range widely from 60% to over 90% [32,33]. Because of the risk
of missed neoplasia in the nonvisualized colon, further tests
may be advisable depending on patients’ risk factors (i. e. left-si-
ded polyps, family history, clinical indication). Such tests usually
consist of radiological imaging (CT-colonography or barium ene-
ma) and/or colonoscopy using different endoscopes (pediatric or
variable-stiffness colonoscopes, balloon-assisted enteroscopes)
or with anaesthetist assistance [34]. The most frequent causes of
incomplete colonoscopy include left-sided angulations caused by
diverticular disease or post-surgical adhesions, extensive loop-
ing, or stenosing colorectal cancer [35]. In preliminary studies,
CCE-1 has been shown to be feasible in this setting, although re-
sults for complete visualization of the colorectal mucosa have
been conflicting, varying between 50% and 89% in small num-
bers of patients [36–38].
To date, there are insufficient data to support the use of CCE in the
diagnostic work-up or in the surveillance of patients with suspect-
ed or known inflammatory bowel disease (IBD) (Evidence level 4,
Recommendation grade D). On the basis of preliminary data, CCE
may be useful to monitor inflammation in ulcerative colitis, which
may help to guide therapy (Evidence level 4, Recommendation
grade D).
Inflammatory bowel diseases (IBDs) frequently involve the colo-
rectal mucosa, with lesions reported in this location in 70–80%
of patients with Crohn’s disease and virtually always in those
with ulcerative colitis [39]. Endoscopy is a suitable test for IBD di-
agnosis, because of its high sensitivity for the detection of muco-
sal lesions and its ability to sample the digestive mucosa. How-
ever, biopsy is usually required to improve test specificity, be-
cause of the possibility of false-positive results [40]. For this rea-
son, colonoscopy is primarily recommended in this setting [41]. It
is also recognized that treatment of ulcerative colitis should be
Table 3 True-positive and false-negative diagnoses of histologically verified
colorectal cancer reported with colon capsule endoscopy (CCE).
Author, year Patients with
cancer, n
True-
positive
False-
negative
First-generation CCE studies
Eliakim, 2006 [7] 0 0 0
Schoofs, 2006 [8] 0 0 0
Van Gossum, 2009 [9] 19 14 5
Sieg, 2009 [10] 1 1 0
Gay, 2010 [11] 0 0 0
Sacher-Huvelin, 2010 [12] 5 3 2
Pilz, 2010 [13] 0 0 0
Spada, 2011 [14] 1 1 0
Spada, 2011 [15] 1 1 0
Second-generation CCE studies
Eliakim, 2009 [18] 1 1 0
Spada, 2011 [20] 3 3 0
Spada C et al. Colon capsule endoscopy: ESGE Guideline… Endoscopy 2012; 44: 527–536
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tailored to the severity of colonic inflammation and that long-
lasting ulcerative colitis is associated with an increased risk of
colorectal dysplasia and cancer [42,43]. Small-bowel capsule en-
doscopy provides a very high diagnostic yield for small-bowel
mucosal lesions and its use is recommended in specific scenarios
of IBD [40]. Similarly, CCE could be used to identify mucosal
changes in the colorectal mucosa.
To date, the role of CCE in IBD has been evaluated in only one ser-
ies [44]. Specifically, CCE has been compared with colonoscopy
with the aim of evaluating its accuracy in monitoring colonic in-
flammation in patients with suspected or known ulcerative coli-
tis. In this preliminary experience, CCE yielded encouraging re-
sults for detecting active ulcerative colitis (i. e., sensitivity 77%,
specificity 78%) and substantial agreement with colonoscopy
[44].
Contraindications for CCE are similar to those for small-bowel cap-
sule endoscopy. The use of sodium phosphate as a booster should
be avoided in patients at increased risk of sodium phosphate toxicity.
Other kinds of booster preparations are under investigation andmay
be considered in patients at increased risk of sodium phosphate toxi-
city (Evidence level 4, Recommendation grade D).
CCE entails a similar technology to small-bowel capsule endosco-
py, so that contraindications to small-bowel capsule endoscopy
apply to CCE. The most frequent contraindications to capsule en-
doscopy are: dysphagia or swallowing disorder, prior major ab-
dominal surgery of the gastrointestinal tract, known or suspect-
ed bowel obstruction, presence of a cardiac pacemaker or other
implanted electromedical devices, and pregnancy [45]. In con-
trast to small-bowel capsule endoscopy, no data on safety of CCE
in pediatric patients are available.
In addition to contraindications inherent to the capsule device,
further contraindications can exist because the CCE procedure
may imply the administration of sodium phosphate, although at
lower doses than those usually used for bowel preparation for co-
lonoscopy [18,20]. However, to be prudent, all the contraindica-
tions to use of sodium phosphate should be extended to CCE. In
particular, sodium phosphate use should be avoided in elderly
persons as well as in patients with hypovolemia, baseline kidney
disease, bowel obstruction, or active colitis, and also in thosewho
are usingmedications that affect renal perfusion or function [46].
In patients with contraindications to sodium phosphate, alterna-
tive booster agents (see section on bowel preparation) may be
considered.
The risk of capsule retention with CCE is very low. In the case of
capsule retention either in the small or the large bowel, endoscopy
or surgery can be considered on the basis of the clinical background
(Evidence level 3, Recommendation grade D).
Capsule retention is a major complication of small-bowel capsule
endoscopy, with an overall incidence of 1–2%, although reported
rates widely vary between 0% and 21% depending on the indica-
tion for the examination [45]. Available studies with CCE, despite
the larger capsule size, have not reported any capsule retention
or sticking either in the small bowel or in the colon [7–20]. Of
note, a case of CCE where a stuck colonic capsule was passed
through a malignant colonic stricture and removed with the aid
of flexible colonoscopy has recently been reported [47]. Removal
of colonic capsule retained in the small bowel may require sur-
gery, although removal by device-assisted enteroscopy may be
an option [45]. Patients’ symptoms and the possible pathology
identified by CCE must also be taken into account in choosing
the most appropriate treatment for capsule retention. Albeit in-
frequently, mild nausea, abdominal pain, and vomitingmay occur
during CCE and are attributed to colon preparation [7–18,20].
Antiemetic drugs have been empirically used to manage these si-
tuations.
5.Bowel preparation for CCE
!
Patients must follow a liquid diet the day before the procedure,
whilst the role of low-residue diet is yet to be clarified (Evidence
level 4, Recommendation grade D).
For conventional colonoscopy, a low-residue diet is often recom-
mended during the 3 to 5 days before the bowel cleansing proto-
col itself. The aim is to decrease the amount of solid stool in the
colon and thus reinforce the lavage effect of polyethylene glycol
(PEG) solutions. This recommendation is reinforced when low-
volume cleansing protocols are proposed. However, very few
studies have adequately addressed the efficacy of this low-resi-
due diet before colonoscopy. On the other hand, when CCE is con-
sidered, recent experience seems to suggest that a clear liquid
diet on the day before the procedure might improve the quality
of bowel cleansing and consequently the diagnostic yield of CCE
[9,11,12,18,20]. Therefore, diet recommendations (i.e., liquid
diet the day before, low residue diet 3–5 days before CCE) have
generally been adopted in the studies published so far. However,
the prescription of diet restrictions over several days before the
CCE may impair patient compliance with the cleansing protocol.
A total of 4L of PEG should be administered before the CCE proce-
dure. A split-dosage regimen with intake the day before and on the
day of the examination seems advisable to increase the tolerability
and the efficacy of the preparation (Evidence level 4, Recommenda-
tion grade D).
Booster preparations need to be given to improve capsule egestion
rates and to complete visualization of the colonic mucosa (Evidence
level 4, Recommendation grade D). In patients without contraindica-
tions to sodium phosphate, boosters based on sodium phosphate
should be used (Evidence level 1+ , Recommendation grade B). Low-
dose sodium phosphate boosts have been shown to achieve an ade-
quate CCE egestion rate and should be preferred over higher sodium
phosphate doses (Evidence level 4, Recommendation grade D).
During CCE, as the capsule is not equipped to insufflate the colon,
aspirate liquids, wash the mucosal surface, and move actively
along the gut, the cleansing protocol cannot be restricted to the
time before the procedure but must be continued intraprocedu-
rally [7–15,18,20]. The cleansing protocol for CCE aims at: (i)
adequately cleansing the colonic mucosa, (ii) filling the colonic
lumen with clear liquids to improve mucosal visualization and
to decrease the number of air bubbles, and (iii) facilitating cap-
sule progression so that it reaches the anal verge before the end
of the battery life. Unpublished preliminary trials showed that a
standard colonoscopy preparation could not achieve these tasks.
Three trials demonstrated the efficacy of a protocol combining
PEG and boosts with sodium phosphate to provide adequate
bowel cleansing and high rates of complete colon examination
[9,10,12]. Such a combined protocol has been applied in most
subsequent studies although modifications in the timing and do-
ses of the components have been reported. Starting from the ex-
perience with bowel cleansing for colonoscopy, lavage solutions
with large volumes (3–4L) of PEG solutions have been used in
most studies with CCE [7–15,18,20]. Very little experience with
lower doses of PEG or substitutes such as sodium phosphate or
magnesium citrate is currently available [48]. Studies demon-
strating the equivalence of lower-volume cleansing and PEG pro-
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tocols for conventional colonoscopies cannot therefore be exten-
ded to CCE [49]. Two main split regimens of PEG have been pro-
posed: “3+1” (i. e., 3L of PEG the day before and 1L on the day of
CCE) [7–9,11,14], or “2+2” (i. e., 2L of PEG the day before and 2L
on the day of CCE) [15,18,20]. Although no comparative study is
available, the 2+2 regimen seems to be more acceptable to pa-
tients and equally effective in terms of colon cleanliness.
To meet the specific goals of bowel cleansing for CCE discussed
above, sodium phosphate boosts have been added to the usual
PEG and diet recommendations used for conventional colonosco-
py. The role of the boosts administered during capsule progres-
sion is not limited to increasing and/or maintaining colonic
cleanliness but also includes a propulsive effect by means of a
volume effect allowing the capsule to move in a watery environ-
ment. The propulsive effect of the sodium phosphate boosts re-
sults in an effective transit of the CCE device through the small
and large bowels with a higher rate of capsule expulsion within
the limited operating time of the capsule battery [8–15,18,20].
Magnesium sulfate has not been tested in this indication. How-
ever, a recent randomized study compared boosting with sodium
phosphate to boosting with small volumes of PEG and concluded
that the rate of capsule expulsion was higher with sodium phos-
phate [14]. The cumulative dose of sodium phosphate booster
adopted initially in CCE studies was 75mL [8,9]. In order to re-
duce the risk of side effects from sodium phosphate administra-
tion, a lower dose (45 or 55mL, in total) has been used in the
most recent studies on CCE-2, with no apparent decrease in cap-
sule egestion rate [18,20].
Potential adverse events caused by bowel preparation for CCE
mainly appear to be related to sodium phosphate administration.
Although no serious sodium phosphate-related adverse event
has been reported up to now, after more than 1000 CCE examina-
tions [7–18,20], use of sodium phosphate should be avoided in
patients at higher risk of sodium phosphate toxicity (i. e. elderly
persons, patients with hypovolemia, baseline kidney disease,
bowel obstruction, or active colitis, patients on medications af-
fecting renal perfusion or with function kidney failure, or having
concomitant treatment with angiotensin-converting enzyme
(ACE)-inhibitors, etc.) [46].
During the CCE procedure, the use of prokinetics is recommended
when the capsule stays in the stomach longer than 1 hour (Evidence
level 4, Recommendation grade D).
Prokinetics have been added to the protocol of bowel preparation
for CCE mainly to stimulate the progression of the capsule in the
upper gut, especially the stomach. In initial studies, tegaserod [7]
and domperidone [8] were used. Domperidone was also used in
multicenter trials [9,11,12]. No comparative study has so far
been reported that assessed the usefulness of one dose of a pro-
kinetic administered 15 minutes before capsule ingestion. With
CCE-2, the data recorder allows real-time viewing of endoscopic
images provided by the capsule; administration of prokinetics
has thus been limited to cases where the capsule had not entered
the small bowel within 1 hour after ingestion [18,20].
Written and oral information about CCE bowel preparation should
be delivered by healthcare professionals (physician or nurse) in-
volved in gastroenterology and with experience regarding the tech-
nique (Evidence level 4, Recommendation grade D).
It is essential to strongly emphasize to the patient the need for
good bowel preparation, since the quality of bowel preparation
has been found to relate to the accuracy of the CCE procedure
[9]. Experience with conventional colonoscopy shows that de-
tailed information must be given to the patient before the proce-
dure. The instructing person may be the endoscopist himself or
herself, the referring physician, or an experienced and endosco-
py-trained nurse [50]. Beyond the issues of quality and necessity
of information with regard to bowel preparation, monitoring or
“coaching” the patient during the cleansing protocol might be
helpful to improve bowel cleansing.
6.Reporting and work-up of CCE results
!
The CCE report should provide information on the quality of prepara-
tion, technical details of the examination, completeness of the proce-
dure, and on the significant findings (polyps/masses ≥6mm, or ≥3
polyps irrespective of size) in a standardized fashion (Evidence level
4, Recommendation grade D). In particular, size, morphology, and lo-
cation should be separately described for each polyp. Extracolonic
findings should also be reported when clinically meaningful (Evi-
dence level 4, Recommendation grade D).
Patients found to have a polyp ≥6mmat CCE, aswell as thosewith ≥3
polyps irrespective of size, should be sent for post-CCE colonoscopy for
polypectomy (Evidence level 4, Recommendation grade D).
Patients without significant findings at CCE should repeat CCE or a
different screening test after 5 years, unless bowel preparation at
CCE was inadequate (Evidence level 4, Recommendation grade D).
Quality of bowel preparation has been related to CCE accuracy for
relevant lesions [9]. Mucosal visualization by CCE may be ham-
pered by feces, turbid fluids, or bubbles. Scoring on all these
items has recently been included in a grading system that al-
lowed evaluation of colon cleansing for CCEwith good interobser-
ver agreement (●" Table4) [51].
A CCE examinationmay be incomplete, mainly because a slow co-
lonic transit that may mean that the battery is exhausted while
the CCE device is still in the colon. Therefore, some colorectal
Table 4 Cleansing level scale and
bubbles effect scale [51].
Rating Description
Cleansing level
scale
Poor Inadequate
Large amount of fecal residue precludes a complete examination
Fair Inadequate but examination completed
Enough feces or turbid fluid to prevent a reliable examination
Good Adequate
Small amount of feces or turbid fluid not interfering with examination
Excellent Adequate
No more than small bits of adherent feces
Bubbles effect
scale
Significant Bubbles that interfere with the examination
More than 10% of surface area obscured by bubbles
Insignificant No bubbles or bubbles that do not interfere with the examination
Less than 10% of surface area obscured by bubbles
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segments (usually the left colon) may not be visualized by CCE,
potentially leading to false-negative results.
Most colonic polyps discovered at screening are diminutive, with
negligible risk of harboring advanced features (high grade dys-
plasia, villous component, or malignancy) [52–55]. Moreover,
40% of diminutive colonic polyps are hyperplastic rather than
adenomatous [56]. Diminutive lesions identified by a noninva-
sive test may also be missed by the post-test colonoscopy, be-
cause of the imperfect sensitivity of the latter for diminutive le-
sions [57,58]. By extrapolating data from CT colonography stud-
ies thatmodelled the impact of colonoscopy or continued surveil-
lance for diminutive polyps discovered at CT-colonography, it can
be concluded that referral for removal of diminutive lesions
found at CCEmight carry an unjustified burden of costs and com-
plications relative to a minimal gain in clinical efficacy [59,60].
Moreover, studies on second-generation CCE only provide accu-
racy data relating to lesions ≥6mm in size, its specificity for di-
minutive lesions being largely unknown [18,20]. Thus, the only
exception regarding post-CCE referral for diminutive polyps is
the simultaneous presence of at least 3 of these lesions. Polyp
multiplicity has appeared as a strong predictive factor of subse-
quent advanced neoplasia development in post-polypectomy fol-
low-up studies [61]. Most advanced neoplasias have been shown
to be restricted to the relatively small proportion of patients with
polyps ≥6mm in size [55]. Consequently, post-CCE colonoscopy
referral of such patients may be expected to lead to a substantial
reduction of the prevalence of advanced neoplasia in patients in-
itially evaluated with CCE. Although it has been shown that pa-
tients with polyps of size 6–9mm may be safely followed up for
a relatively short period of time [62–64], there is no evidence
that CCE repetition after 2–3 years may lead to re-identification
of the previously unremoved polyp.
The efficacy of a noninvasive test such as CCE ultimately depends
on the identification and removal/biopsy sampling at post-CCE
colonoscopy of the lesions found at CCE. For this reason, it is cri-
tically important that the size, morphology, and location of le-
sions should be accurately described, to facilitate the post-CCE
identification at colonoscopy. The Paris classification may be ex-
tended to CCE to standardize polyp reporting [65].
Similarly to small-bowel capsule endoscopy, CCE may detect
clinically important extracolonic findings, such as preneoplastic
(i. e. Barrett esophagus), ulcerative, or malignant processes of the
upper gastrointestinal tract or the small bowel. Although the im-
pact of CCE diagnosis on the course of these extracolonic diseases
has not been addressed, appropriate patient care requires that
the presence of clinically important abnormalities should be
identified and effectively communicated.
The long-term efficacy of CCE with regard to CRC prevention is
unknown at present. A 5-year interval before repeating a new
screening test has been recommended for other noninvasive
imaging procedures, such as flexible sigmoidoscopy, CT colono-
graphy, or barium enema [25]. Considering that the sensitivity
of CCE appears to be comparable to that of these tests, the 5-
year interval may be extended to CCE by analogy.
If overall bowel preparation was deemed inadequate or CCE was
incomplete, repetition of an imaging study should be considered
[Evidence level 4, Recommendation grade D].
There is an association between the cleanliness level and the ac-
curacy of CCE for detecting polyps [9]. False-negative CCE find-
ings have also been related to incomplete visualization of the
colorectal mucosa because of CCE battery exhaustion [16]. Al-
though possible predictors of inadequate bowel preparation at
CCE have not yet been analyzed, the effectiveness of bowel pre-
paration has been shown at colonoscopy to depend on a number
of factors, the most important of which is compliance [66–68].
Other independent risk factors for incomplete colon preparation
include a history of constipation, inpatient status, use of antide-
pressants, and male gender [68]. In the case of inadequate colon
cleansing at CCE or of incomplete visualization of the colorectal
mucosa, it may not be possible to exclude even large lesions in
the poorly visualized or unvisualized areas. For this reason, based
on clinical background, repetition of CCE or a different imaging
test may be considered. For a follow-on procedure, whichever
one is recommended, the potential reasons for inadequate CCE
preparation should be addressed. Poor compliance might be ad-
dressed by better education and supervision, and by changing
the type and/or intensity of bowel preparation.
Use of this Guideline
!
The aim of this Guideline is to provide caregivers with a compre-
hensive framework on how to implement and practice CCE in a
clinical setting. ESGE Guidelines represent a consensus of best
practice based on the available evidence at the time of prepara-
tion. Theymay not apply in all situations and should be interpret-
ed in the light of specific clinical situations and resource availabil-
ity. Further controlled clinical studies may be needed to clarify
aspects of these statements, and revision may be necessary as
new data appear. Clinical considerationmay justify a course of ac-
tion at variance to these recommendations. ESGE Guidelines are
intended to be an educational device to provide information that
may assist endoscopists in providing care to patients. They are
not rules and should not be construed as establishing a legal
standard of care or as encouraging, advocating, requiring, or dis-
couraging any particular treatment.
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